Meningococcal disease is caused by Neisseria meningitidis, which can infect the lining of the brain and the spinal cord, causing meningitis. Strains of the bacteria can also cause serious bloodstream infections.
N meningitidis can also live silently in a person's nose and throat, without illness. These "colonised" carriers can spread the pathogen to others through close contact.
In the study, researchers placed drops containing low doses of Neisseria lactamica, a related but harmless bacterial strain, into the noses of 149 healthy university students in the UK.
Among students who received the N lactamica drops and became colonised, the harmless bacteria appeared to prevent N meningitidis from colonising the students' throats.
The "good" bacteria also displaced the worrisome pathogen in those who were already carrying it when the study began.
The effect was seen after just two weeks, when the number of students carrying N meningitidis in their upper airway dropped by 9.5 per cent among those who were also colonised by N lactamica using the drops. The effect lasted for at least four months.
Meningococcal vaccines induce high levels of antibodies in the blood to ward off infection, but current vaccines also limit "carriage" of N meningitidis in the throat, preventing its spread from one person to another.
The drop in carriage seen in this study was faster and more persistent than that seen after vaccination. The harmless bacterial strain was also active against more varieties of N meningitidis.
The research is published in the journal Clinical Infectious Diseases.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
